top of page

Our People

Academic Staff
​Prof. Joey Zu-yao YANG 楊祖耀教授

Prof. Joey Zu-yao YANG


BMedSc (PKU), MMedSc (PKU), PhD (CUHK)

Assistant Professor


Professor Yang obtained his Bachelor degree in Preventive Medicine and Master Degree in Epidemiology and Biostatistics from Peking University and PhD in Public Health from the Chinese University of Hong Kong. He is specialized in epidemiological methods, especially systematic reviews, and is heavily involved in the teaching of epidemiology courses for both undergraduate and postgraduate programmes. Professor Yang has authored more than 60 publications, including those appearing in highly respected journals such as British Medical Journal and Annals of Internal Medicine. He also serves as a peer reviewer for more than 20 international journals.

Research Interests

  • Prognostic factors of and treatment effects on major chronic diseases

  • Risk factors and primary prevention of cardiovascular diseases

  • Evidence-based medicine: over-diagnosis and over-treatment

  • Research waste

Recent Funded Research Projects 

  • Estimating the magnitude of over-diagnosis of thyroid cancer and prostate cancer in mainland China: a modelling study based on national registry data. The Chinese University of Hong Kong Direct Grant for Research 2019/2020, HK$ 62,000, 30 June 2020 - 29 June 2021, the principal applicant

  • Relationship between skin rash and clinical outcomes in advanced pancreatic cancer treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. Health and Medical Research Fund, Food and Health Bureau, 2017.07.24-2018.07.23, HK$ 431,260.00, the principal applicant

  • Faculty Postdoctoral Fellowship Scheme, the Chinese University of Hong Kong, HK$360,000.00, 2014.04-2016.04, the principal applicant

  • The concordance of KRAS, BRAF, PIK3CA, and PTEN status between primary tumors and corresponding metastases in patients with colorectal cancer: a systematic review and meta-analysis, Health and Medical Research Fund, Food and Health Bureau, 2015.07.01-2016.06.30, HK$ 356,664.00, the 2nd applicant

  • The predictive biomarkers for EGFR tyrosine kinase inhibitors treatment in patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials, Health and Medical Research Fund, Food and Health Bureau, 2014.01.01-2014.12.31, HK$ 214,416.00, the 2nd applicant

  • The association between molecular biomarkers in EGFR downstream signaling pathway and clinical outcomes of cetuximab treatment in patients with metastatic colorectal cancer, Health and Medical Research Fund, Food and Health Bureau, 2013.06.01-2016.05.31, HK$ 981,720.00, the 5th applicant

  • Design and evaluating a new model to determine whose cholesterol should be measured for primary prevention, National Natural Science Foundation of China, 2013.01.01-2016.12.31, RMB 850,000.00, the 7th applicant

Selected Publications

  1. Feng Q, Zhou A, Zou H, Ingle S, May MT, Cai W, Cheng CY, Yang Z (corresponding author), Tang J. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;366:I4179.

  2. Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer 2017;140(12):2805-2819.

  3. Yang Z, Fan H, Tang J. Guidance for modifying disease definition. JAMA Intern Med. 2017;177(12):1872-3.

  4. Yang ZY, Yu YY, Yuan JQ, Shen WX, Zheng DY, Chen JZ, Mao C, Tang JL. The prognostic value of phosphatase and tensin homolog negativity in breast cancer: a systematic review and meta-analysis of 32 studies with 4393 patients. Crit Rev Oncol Hematol 2016;101:40-9.

  5. Yang ZY, Scott CA, Mao C, Tang JL, Farmer AJ. Resistance exercise versus aerobic exercise for type 2 diabetes: a systematic review and meta-analysis. Sports Med 2014; 44(4):487-99.

  6. Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev 2014; 11:CD009948.

  7. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 2013; 133(8):1914-25.

  8. Yang ZY, Mao C, Tang JL. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2012; 366(8):767.

  9. Yang ZY, Shen WX, Hu XF, Zheng DY, Wu XY, Huang YF, Chen JZ, Mao C, Tang JL. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: meta-analysis. J Hematol Oncol 2012;5(1):52.

  10. Yang ZY, Mao C, Tang JL. Depression and Risk of Stroke. JAMA 2011; 306(23):2562-3.

Last Updated: 27 July 2020

bottom of page